| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Carboplatin-d4 targets the same molecular pathways as its parent compound, Carboplatin. The unlabeled Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription, and induces cell death. It functions as a DNA alkylator/crosslinker, forming intra-strand and inter-strand DNA crosslinks, ultimately activating apoptosis pathways. As a deuterated internal standard, the labeled form is used for accurate quantification rather than for pharmacological targeting.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
Carboplatin-d4 is not used for in vitro biological activity assays, as it is an analytical standard. The parent compound Carboplatin exhibits potent cytotoxic activity against a broad range of cancer cell lines. It induces cell death by binding to DNA, forming platinum-DNA adducts that inhibit DNA replication and transcription, leading to cell cycle arrest and apoptosis. Its activity is typically measured using cell viability assays such as MTT or CellTiter-Glo. |
| ln Vivo |
Carboplatin-d4 is not used for in vivo efficacy studies, as it is a stable isotope-labeled internal standard. The parent compound Carboplatin is widely used clinically as an anti-cancer agent for the treatment of ovarian, lung, and other solid tumors. In research settings, it is studied in xenograft mouse models where it significantly inhibits tumor growth. Carboplatin-d4 is used as a tracer in pharmacokinetic studies to quantify Carboplatin concentrations.
|
| Enzyme Assay |
As an analytical standard, Carboplatin-d4 is used in non-cellular mass spectrometry assays. The protocol involves spiking a known amount of Carboplatin-d4 into a biological sample (e.g., plasma, urine, or tissue homogenate). After sample preparation (such as protein precipitation or solid-phase extraction), the extract is analyzed by LC-MS/MS. The compound is then used to correct for analyte recovery, matrix effects, and instrument variability.
|
| Cell Assay |
Carboplatin-d4 is not used for in vitro cellular assays as a functional agent. For analytical applications, cell culture media or cell lysates from experiments with unlabeled Carboplatin can be spiked with Carboplatin-d4. This mixture is then processed and analyzed by LC-MS/MS to quantify the concentration of Carboplatin. This allows researchers to study the uptake, metabolism, and stability of the drug in cellular environments.
|
| Animal Protocol |
In pharmacokinetic studies, Carboplatin-d4 serves as the internal standard to quantify the concentration of the parent drug Carboplatin. An animal model (e.g., rat or mouse) is administered Carboplatin via intravenous or intraperitoneal routes. Blood samples are collected at various time points post-dose, and plasma is separated. A known amount of Carboplatin-d4 is added to each plasma sample as an internal standard before extraction and LC-MS/MS analysis, allowing calculation of key PK parameters.
|
| ADME/Pharmacokinetics |
Carboplatin-d4 is a stable isotope-labeled compound used as an internal standard for LC-MS/MS quantification. It has a distinct molecular weight of 375.28 (C₆H₈D4N2O4Pt) due to the replacement of four hydrogen atoms with deuterium. The deuterium labeling does not significantly alter its chromatographic behavior, allowing for co-elution with the analyte. It is soluble in aqueous solvents and DMSO. Deuteration has potential to affect the pharmacokinetic and metabolic profiles of drugs.
|
| Toxicity/Toxicokinetics |
Toxicological data for Carboplatin-d4 are not reported separately, as it is an analytical internal standard. The parent compound Carboplatin, as a platinum-based chemotherapeutic agent, has well-characterized toxicities including myelosuppression (thrombocytopenia, neutropenia, anemia), nephrotoxicity (less than cisplatin), ototoxicity, and gastrointestinal effects. As a research-use stable isotope-labeled compound used at low concentrations, Carboplatin-d4 does not pose significant additional risks. Standard chemical safety precautions apply.
|
| References |
|
| Additional Infomation |
Carboplatin-d4 (NSC 241240-d4) has the molecular formula C₆H₈D4N2O4Pt and a molecular weight of 375.28. The parent compound CAS number is 41575-94-4. It appears as a white to off-white solid powder. The product has a purity of ≥99.0%. It is stored at -20degC under inert conditions. The deuterium atoms are incorporated into the cyclobutane ring of the molecule. The compound is for research use only.
|
| Molecular Formula |
C6H8D4N2O4PT
|
|---|---|
| Molecular Weight |
375.28
|
| Related CAS # |
Carboplatin;41575-94-4
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6647 mL | 13.3234 mL | 26.6468 mL | |
| 5 mM | 0.5329 mL | 2.6647 mL | 5.3294 mL | |
| 10 mM | 0.2665 mL | 1.3323 mL | 2.6647 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
